We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Two Weeks of Voluntary Reduced Physical Activity in Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02221804
Recruitment Status : Unknown
Verified August 2014 by Royal Brompton & Harefield NHS Foundation Trust.
Recruitment status was:  Recruiting
First Posted : August 20, 2014
Last Update Posted : August 22, 2014
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Chronic Obstructive Pulmonary Disease (COPD) is the most common pulmonary disease, responsible for considerable morbidity and mortality and is the third leading cause of death worldwide. As well as its consequences in the lungs, COPD is well recognized to be associated with a range of important systemic consequences and co-morbidities. Interestingly, skeletal muscle dysfunction is noted in both early and advanced disease, suggesting its origins may not be wholly pulmonary.

Treatment strategies targeting lung function are, unfortunately, of limited value. Given the burden of disease, it is becoming increasingly important that investigative and therapeutic work now focuses on other systemic characteristics and sequelae which define the disease phenotype.

This is a randomized controlled trial of the effect of 14 days of voluntary reduced activity on muscle mass, muscle strength, body composition, and atrophy signalling in patients with COPD and age-matched controls.

The primary hypothesis upon which this study is based is that a short reduction in ambulation will induce a transient reduction in quadriceps muscle mass, quadriceps strength and physical performance in patients with COPD compared to matched COPD patients whose mobility has not been restricted.

The secondary hypothesis is that the magnitude of the above changes will be greater in physically inactive COPD patients compared to physically inactive age-matched controls.

The overall aim of this research is to use an in vivo human model of 14 days of voluntary reduced physical activity to test the above hypotheses. If the model proves feasible, this will allow for earlier proof of concept studies of novel therapeutic agents.


Condition or disease Intervention/treatment
Chronic Obstructive Pulmonary Disease (COPD) Muscle Atrophy Behavioral: 14 days of voluntary step count reduction to no more than 1500 steps/day.

Detailed Description:

This is a non-commercial randomized controlled trial. 15 patients with COPD and 15 age-matched controls will voluntarily reduce their daily step-count to no more than 1500 steps/day, from a baseline of > 3500 steps/day.

Before and after 14 days of reduced daily step-count, these 30 participants will undergo measures of appendicular mass, quadriceps strength, exercise tolerance and blood and urinary biomarkers. Quadriceps muscle biopsies will also be taken before and after the 14-day intervention.

15 patients with COPD will be studied 14 days apart but will not undergo the intervention.


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Effect of Two Weeks of Voluntary Reduced Physical Activity in COPD - A Novel Methodology for Anabolic Drug Development
Study Start Date : May 2014
Estimated Primary Completion Date : April 2016
Estimated Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: COPD - reduced activity levels
COPD patients who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
Behavioral: 14 days of voluntary step count reduction to no more than 1500 steps/day.
Experimental: Healthy - reduced activity levels
Healthy age-matched controls who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
Behavioral: 14 days of voluntary step count reduction to no more than 1500 steps/day.
No Intervention: COPD - unchanged activity levels


Outcome Measures

Primary Outcome Measures :
  1. Quadriceps muscle mass as measured by dual-energy x-ray absorptiometry (DEXA) after two weeks of voluntary reduced physical activity. [ Time Frame: Change from baseline in quadriceps muscle mass at 14 days. ]

    Dual-energy X-ray absorptiometry (DEXA) scanning will be used to assess body composition.

    Two X-ray beams with different energy levels are used during this technique. It is a widely used scanning modality and is entirely painless. The radiation received by the patient during the scan is less than that of an airline flight from California to New York and back.

    Specifically, appendicular lean composition will be measured (g).



Secondary Outcome Measures :
  1. Quadriceps strength determined as maximal voluntary contraction force (QMVC) and the force elicited by unpotentiated supramaximal stimulation of the femoral nerve (TwQ). [ Time Frame: Before and after the 14 day intervention ]

    Subjects sit on a specially designed chair keeping the knee flexed at 90 degrees over the end. Force is measured via an inextensible strap placed around the ankle and connected to a strain gauge. Subjects are asked to extend their knee maximally against the strap with visual feedback and verbal encouragement from the investigator, until no further increased in QMVC occurs.

    QMVC is reported in kg and is the highest single value obtained.

    In addition, the strength and endurance of the quadriceps will be measured using magnetic femoral nerve stimulation (TwQ). This is used to determine muscle strength in a non-volitional manner. The nerve to be studied is depolarised by the application of a rapidly changing magnetic field produced by a coil positioned on the overlying skin surface. The magnetic field is relatively unimpeded by skin, fat and bone, and thus has the ability to stimulate deep nerves easily and with little discomfort.


  2. Rectus Femoris Cross Sectional Area determined by Quadriceps Ultrasound (RFCSA US) [ Time Frame: Before and after the 14 day intervention ]

    An ultrasound (US) scan is a painless test that uses sound waves to create images of organs and structures. We will use it to assess the thickness of the thigh muscles.

    The patient rests in a reclined position for this test, and a lubricating jelly is applied to the thigh. The US probe is moved over the thigh area to produce a picture of the size of the thigh muscle. The leg to be scanned will be the same leg used for QMVC.

    The units of measure for the RFCSA are cm2.


  3. 6 minute walk distance (6MWD) [ Time Frame: Before and after the 14 day intervention ]

    The 6MWD is a practical and simple test that measures the distance that a subject can walk quickly on a flat, hard surface in a period of 6 minutes. This will be performed by appropriately trained study site personnel.

    The outcome of the 6MWD will the walking distance covered in meters. The test will be performed according to the ATS Guidelines, in a standardized manner.


  4. Short Physical Performance Battery (SPPB) [ Time Frame: Before and after the 14 day intervention ]

    The SPPB is a brief performance test used to assess how well a subject can perform simple movements that represent the foundation of daily activities. The components that are assessed are 1) a Standing Balance Test, 2) a Four Meter Gait Speed and 3) a Sit to Stand Test. This collection of tests is routinely used in gerontology.

    It is scored out of a total of 12 points (4 for each of the 3 parameters aforementioned).


  5. Blood and urinary biomarkers [ Time Frame: Before and after the 14 day intervention ]

    Serum and plasma aliquots will be prepared from the blood samples for mediator analysis. Analysis will include full blood count, urea and electrolytes, d-dimers, and markers of systemic inflammation (C-reactive protein & fibrinogen). Each donation of blood will not exceed 50mL per study visit.

    Urine samples will be collected and frozen. These will be available for testing potentially relevant biomarkers which may come under investigation within our group.


  6. Atrophy signalling determined from muscle biopsies [ Time Frame: Before and after the 14 day intervention ]
    Muscle biopsies will be taken from the leg quadriceps muscle. These will be assessed for the presence of atrophy and hypertrophy signalling changes. The exact signalling panel will be determined from the most current literature review but is likely to include atrophic markers including myostatin, atrogin and MURF-1, hypertrophic markers including GSK3b, p70S6K and 4E-BP1, together with related microRNAs currently under investigation in our group.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non-smoking adult patients with COPD (GOLD stage II-IV)
  • Non-smoking, healthy, age-matched controls
  • Baseline step count > 3500 steps/day
  • Baseline 6 minute walk distance > 140m

Exclusion Criteria:

  • Inability to provide written, informed consent
  • Significant co-morbidity limiting exercise tolerance
  • Within 1 month of acute exacerbation of COPD
  • Within 1 month of pulmonary rehabilitation
  • History of venous thrombo-embolism or known increased risk of thrombotic disease
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02221804


Contacts
Contact: Sara Kladidis, MB BS MRCP 02073518029 s.kladidis@rbht.nhs.uk

Locations
United Kingdom
Royal Brompton & Harefield NHS Foundation Trust Recruiting
London, United Kingdom, SW3 6NP
Contact: Sara Kladidis, MB BS MRCP    02073518029    s.kladidis@rbht.nhs.uk   
Principal Investigator: Michael Polkey, FRCP PhD         
Sponsors and Collaborators
Royal Brompton & Harefield NHS Foundation Trust
Investigators
Principal Investigator: Michael Polkey, FRCP PhD Royal Brompton & Harefield NHS Foundation Trust
More Information

Responsible Party: Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT02221804     History of Changes
Other Study ID Numbers: 2014LF002B
First Posted: August 20, 2014    Key Record Dates
Last Update Posted: August 22, 2014
Last Verified: August 2014

Keywords provided by Royal Brompton & Harefield NHS Foundation Trust:
Physical Inactivity
Skeletal Muscle
Cachexia

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Atrophy
Muscular Atrophy
Respiratory Tract Diseases
Pathological Conditions, Anatomical
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms